SCHEMBL254822

SCHEMBL254822

COc1c(Cl)cccc1Cl

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.46
ALDH1A1 P00352 5/20 0.46
HSD17B10 Q99714 1/20 0.46
MAPK1 P28482 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
CYP1A2 P05177 1/20 0.43
CYP2A6 P11509 1/20 0.43
RAB9A P51151 3/20 0.42
NPC1 O15118 2/20 0.42
TSHR P16473 2/20 0.42
LMNA P02545 1/20 0.42
PKM P14618 1/20 0.42
L3MBTL1 Q9Y468 3/20 0.42
HPGD P15428 1/20 0.42
KMT2A Q03164 1/20 0.41
NOTUM Q6P988 1/20 0.41
GAA P10253 3/20 0.40
MAPT P10636 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29048096 0.95 KDM4E (0.43) KDM4EALDH1A1HSD17B10MAPK1SMN1; SMN2
SCHEMBL16733990 0.90 KDM4E (0.45) KDM4EALDH1A1HSD17B10MAPK1SMN1; SMN2
SCHEMBL197298 0.85 SMN1; SMN2 (0.50) KDM4EALDH1A1HSD17B10MAPK1SMN1; SMN2
SCHEMBL3236165 0.85 RAB9A (0.50) KDM4EALDH1A1HSD17B10MAPK1SMN1; SMN2
SCHEMBL2094513 0.83 KDM4E (0.44) KDM4EALDH1A1HSD17B10MAPK1SMN1; SMN2
SCHEMBL1703057 0.83 TAS1R3 (0.45) KDM4EALDH1A1HSD17B10SMN1; SMN2KMT2A
SCHEMBL3837354 0.83 KDM4E (0.39) KDM4EALDH1A1HSD17B10MAPK1SMN1; SMN2
SCHEMBL1307407 0.83 KDM4E (0.39) KDM4EALDH1A1HSD17B10MAPK1SMN1; SMN2
SCHEMBL21027568 0.83 KDM4E (0.39) KDM4EALDH1A1HSD17B10MAPK1SMN1; SMN2
SCHEMBL110638 0.83 ALDH1A1 (0.52) KDM4EALDH1A1HSD17B10MAPK1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 266 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022023027-A1 NOVEL CHROMIUM-BASED CATALYTIC COMPOSITION AND ASSOCIATED METHOD FOR THE TRIMERISATION OF ETHYLENE TO HEXENE-1 IFP Energies Nouvelles (FR) 2022-02-03 WO claimed
CN-108623581-B Method for preparing paninula compound 中国海洋大学 2021-10-22 CN claimed
EP-2178373-B1 HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS ICAGEN INC (US) 2013-01-23 EP claimed
EP-2536718-A1 HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS Icagen, Inc. (US) 2012-12-26 EP claimed
US-8058274-B2 Heterocycles as potassium channel modulators ICAGEN, INC. (US) 2011-11-15 US claimed
WO-2011102964-A1 HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS ICAGEN, INC. (US) 2011-08-25 WO claimed
EP-2178373-A1 HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS Icagen, Inc. (US) 2010-04-28 EP claimed
US-20090062290-A1 HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS ICAGEN, INC. (US) 2009-03-05 US claimed
WO-2009026254-A1 HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS ICAGEN, INC. (US) 2009-02-26 WO claimed
US-5475155-A Reacting an alpha-haloketone with a phenolic-hydroxyl containing compound and a strong protonic acid; neutralization; dehydrohalogenation; dealkylation THE DOW CHEMICAL COMPANY (US) 1995-12-12 US claimed
US-4346244-A Preparation of chloroalkoxybenzenes RHONE-POULENC INDUSTRIES (FR) 1982-08-24 US claimed
US-12336981-B2 Compounds and compositions for the inhibition of NAMPT VALO HEALTH, INC. (US) 2025-06-24 US disclosed
CN-120136692-A Synthesis method of nemonoxacin malate intermediate 2, 4-difluoro-3-methoxy-1-benzoic acid 浙江昌海制药有限公司 2025-06-13 CN disclosed
CN-120136692-A Synthesis method of nemonoxacin malate intermediate 2, 4-difluoro-3-methoxy-1-benzoic acid 浙江昌海制药有限公司 2025-06-13 CN disclosed
CN-120050872-A X-shaped hole rapid filling electroplating process, device and electroplating liquid 广东硕成科技股份有限公司 2025-05-27 CN disclosed
US-4542243-A HALOALKYLATION, ETHERIFICATION, HYDRODEHALOGENATION, INSECTICIDES MITSUI TOATSU CHEMICALS, INC. (JP) 1985-09-17 US disclosed
US-4538003-A TREATMENT WITH MAGNESIUM OR ZINC ORGANOMETALLIC REAGENTS IN PRESENE OF A NICKEL BIDENTATE OR TRIDENTATE PHOSPHOROUS LIGAND E. I. DU PONT DE NEMOURS AND COMPANY (US) 1985-08-27 US disclosed
EP-0066769-B1 FUNGICIDES FOR THE PROTECTION OF MATERIAL BAYER AG (DE) 1985-07-31 EP disclosed
US-4346244-A Preparation of chloroalkoxybenzenes RHONE-POULENC INDUSTRIES (FR) 1982-08-24 US disclosed
US-4057585-A FROM 1,2,3-TRICHLOROBENZENE AND ALKALI METAL ALKOXIDE SMITHKLINE CORPORATION (US) 1977-11-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090062290-A1 HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS KCNJ2, KCNK2, KCNK17 KDM4E 1373/4885ALDH1A1 2150/4885HSD17B10 2434/4885
US-12336981-B2 Compounds and compositions for the inhibition of NAMPT NAMPT, NNMT, NNT KDM4E 1401/4885ALDH1A1 984/4885HSD17B10 1235/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.